289 related articles for article (PubMed ID: 25900065)
21. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
22. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
[TBL] [Abstract][Full Text] [Related]
23. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
24. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Lamanna N; Jurcic JG; Noy A; Maslak P; Gencarelli AN; Panageas KS; Heaney ML; Brentjens RJ; Golde DW; Scheinberg DA; Zelenetz AD; Weiss MA
J Clin Oncol; 2009 Feb; 27(4):491-7. PubMed ID: 19075280
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
Han HJ; Lu YW; Xia RX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):25-9. PubMed ID: 26913388
[TBL] [Abstract][Full Text] [Related]
27. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
[TBL] [Abstract][Full Text] [Related]
29. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
33. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A; Steurer M; Melchardt T; Weiss L; Gassner FJ; Zaborsky N; Geisberger R; Catakovic K; Hartmann TN; Pleyer L; Voskova D; Thaler J; Lang A; Girschikofsky M; Petzer A; Greil R
Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
37. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
38. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Casak SJ; Lemery SJ; Shen YL; Rothmann MD; Khandelwal A; Zhao H; Davis G; Jarral V; Keegan P; Pazdur R
Oncologist; 2011; 16(1):97-104. PubMed ID: 21212432
[TBL] [Abstract][Full Text] [Related]
39. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
[TBL] [Abstract][Full Text] [Related]
40. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
